Vitamin K2: What It Does, MK-7 vs MK-4 & How Much (2026)
Informational summary of published research — not medical advice. If you take warfarin or another vitamin K antagonist, do not start K2 without your physician.
The short version: vitamin K2 (menaquinone) activates the proteins that route calcium into your bones and away from your arteries. For supplementing, choose MK-7 at 90–200 mcg once daily (not MK-4, which needs a pharmaceutical dose to work), look for an all-trans label, and take it with a fatty meal. It's very safe — no established upper limit — with one big exception: if you take warfarin, don't start it without your doctor. The bone evidence is modest-but-real; the "cleans your arteries" marketing runs well ahead of the trials.
As an Amazon Associate we earn from qualifying purchases — picks are ranked by form quality and cost per day, never commissions.
Vitamin K2 at a glance
- What it is
- Menaquinone — the K2 family of vitamin K (distinct from K1 in leafy greens)
- What it does
- Activates osteocalcin (calcium into bone) and matrix Gla protein (calcium out of arteries)
- Best form
- MK-7 (long half-life; works at mcg doses)
- Typical dose
- 90–200 mcg MK-7 once daily
- Cost per day
- ~$0.07–0.22 for an all-trans MK-7 at 100 mcg
- With vitamin D?
- Sensible pairing, but the "45 mcg per 1,000 IU" ratio is convention, not proven
- Food sources
- Natto (by far the richest), some cheeses, egg yolk, dark chicken meat
- Upper limit
- None established; very low toxicity
- Critical caution
- Interacts with warfarin — do not start without your physician
What is vitamin K2?
Vitamin K comes in two families. K1 (phylloquinone) is the one in leafy greens, and your liver uses most of it for blood clotting. K2 (menaquinone) is a family of related forms — the two that matter for supplements are MK-7 and MK-4 — and it's the form that acts out in your bones and blood vessels. K2 is rare in the Western diet; the richest source by far is natto, a fermented soybean dish, which is why K2 status is much higher in populations that eat it. For the broader K1-and-K2-together picture — including the 90/120 mcg Adequate Intake and a dedicated deep-dive on the warfarin interaction — see our parent vitamin K overview.
What does vitamin K2 do?
K2 is the cofactor that switches on two calcium-handling proteins. Osteocalcin binds calcium into the bone matrix; matrix Gla protein (MGP) inhibits calcium from depositing in artery walls. Without enough K2, both stay in their inactive form. The clearest proof is dramatic: mice bred to lack MGP die within two months from their arteries calcifying. So the mental model is "rebar" — K2 helps direct calcium into the structure of bone and away from the plumbing of your arteries. The mechanism, in depth →
MK-7 vs MK-4: which form?
MK-7, for everyday use. Its long half-life (about three days) means a single 90–200 mcg dose reaches and maintains useful blood levels. MK-4 clears within hours and barely registers at supplement doses — the Japanese bone studies that used it needed a pharmaceutical 45 mg a day (taken as 15 mg three times daily), roughly 250 times a normal MK-7 dose. Unless a doctor is running that high-dose protocol, the standalone products worth buying are MK-7. Full MK-7 vs MK-4 comparison →
How much — and how much with vitamin D?
A trial-anchored MK-7 dose is 90–200 mcg per day; the 3-year bone and arterial studies used 180 mcg. There's no established upper limit — vitamin K has very low toxicity. The one number to treat skeptically is the ubiquitous "45 mcg of K2 per 1,000 IU of vitamin D" ratio: it's a formulation convention, not a validated dose (different sources quote different versions, and no trial has tested a specific ratio). The pairing logic is reasonable — D raises calcium absorption, K2 helps place it — but a standalone 90–200 mcg MK-7 is well supported whether or not it's matched to your D3. More on taking vitamin D with K2 →
What to buy — and what it costs
The good news: an effective K2 supplement is cheap. An all-trans MK-7 at 100 mcg — the trial-grade form and dose — runs about $0.07–$0.22 a day. The only real quality "tax" is making sure it's all-trans (a branded ingredient like MenaQ7) rather than a cheap synthetic that may contain the inactive cis form. Skip the MK-4-only products and anything promising to "clean" your arteries.
| Item | Value ( mcg) |
|---|---|
| MK-7 (effective dose) | 180 mcg |
| MK-4 (trial dose) | 45,000 mcg |
Our picks
Branded MenaQ7 — the all-trans, soy-free ingredient used in the clinical trials, at the standard 100 mcg dose.
The same 100 mcg MK-7 dose at the lowest cost per day — a full year in one bottle.
5,000 IU vegan D3 + 100 mcg MK-7 in one softgel, if you want the pairing in a single pill.
As an Amazon Associate we earn from qualifying purchases. Picks are ranked by form quality and cost per day, never commissions. Compare every option on the best vitamin K2 ranking.
Does it actually work?
Here's the honest picture. For bone, the case is modest but real: K2 reliably improves vitamin-K biomarkers, and one well-run 3-year trial of 180 mcg MK-7 slowed bone-density loss in postmenopausal women — though it doesn't reverse osteoporosis or replace established treatments. For arteries, the mechanism is compelling and the epidemiology is encouraging, but be careful: while K2 improves the biomarkers and modestly improved arterial stiffness in one trial, every recent adequately-powered trial that measured actual calcification — in aortic valves, diabetic arteries, and dialysis patients — came back negative. So K2 supports the system that keeps calcium out of arteries; it does not "clean out" calcium already there.
Food sources
K2 is hard to get from a typical diet. The standout source is natto (fermented soybeans), which is in a different league from everything else. After that come some fermented and aged cheeses (Gouda, Edam, Brie), egg yolk, dark chicken meat, and butter from grass-fed cows. If you don't eat natto — most people outside Japan don't — a supplement is the practical way to get a meaningful MK-7 dose.
Is it safe?
K2 has very low toxicity and no established upper limit, and no adverse effects have been reported at normal intakes. The one interaction that genuinely matters is with warfarin and other vitamin K antagonists: vitamin K opposes these drugs, and even small, inconsistent changes in intake can destabilize them — so anyone on warfarin should not start, stop, or change K2 without their physician and INR monitoring. Newer direct oral anticoagulants (apixaban, rivaroxaban, etc.) don't work through vitamin K, so this interaction isn't expected — but tell your doctor regardless.
How to choose a good one
Two things separate a good K2 supplement from a gamble. First, all-trans MK-7: only the all-trans form is biologically active, and cheap synthetic MK-7 can be contaminated with the inactive cis form — a label that says "all-trans" or names a branded ingredient (like MenaQ7) is your quality signal. Second, soy-free sourcing if you're allergic, since natto-derived MK-7 can carry trace soy (chickpea-fermented options avoid it). Aim for a dose in the studied 90–200 mcg range. See our verified MK-7 picks →
Common myths
- "K2 cleans out or reverses arterial plaque." No — the trials that tested this were negative. K2 supports calcium routing; it doesn't dissolve existing calcification.
- "MK-4 and MK-7 are interchangeable." They're not — MK-4 needs a milligram pharmaceutical dose to do what MK-7 does at micrograms.
- "You must match K2 to your vitamin D at 45 mcg per 1,000 IU." That ratio is convention, not evidence. A standalone 90–200 mcg MK-7 is fine.
- "More K2 is stronger." Benefits track the studied 90–200 mcg range; megadosing hasn't been shown to add anything.
The full guides
Verification check · Vitamin K2
What we could and could not verify about Vitamin K2
Not one Vitamin K2 product in our catalogue appears in the NSF, USP or Informed Sport registries. A “cGMP” line audits the factory, not the Vitamin K2 bottle you would actually receive.
Method: our Vitamin K2 roster matched against the full public registries of third-party-certified supplements in the US — NSF/ANSI 173, USP Verified and Informed Sport, 5,317 listings, retrieved 2026-08-25. Absence means nobody independent has checked that Vitamin K2 product, not that it failed. Full method and limitations.
Frequently Asked Questions
What does vitamin K2 do?
Vitamin K2 activates two proteins that manage calcium: osteocalcin, which binds calcium into bone, and matrix Gla protein, which helps keep calcium out of artery walls. In plain terms, K2 helps route calcium toward your skeleton and away from your arteries. The bone evidence is modest but real; the artery benefit is mechanistically compelling but has not held up in recent hard-outcome trials.
Should I take MK-7 or MK-4?
MK-7, for everyday supplementation. It has a long half-life (about three days), so 90–200 mcg once daily reaches and holds useful blood levels. MK-4 is cleared within hours and is barely detectable at supplement doses — the bone studies that used it needed a pharmaceutical 45 mg a day (taken as 15 mg three times daily), about 250 times a typical MK-7 dose. Choose MK-7 unless a doctor is specifically running the high-dose MK-4 protocol.
How much vitamin K2 should I take with vitamin D?
A reasonable, trial-anchored MK-7 dose is 90–200 mcg per day; the 3-year studies used 180 mcg. The popular "45 mcg of K2 per 1,000 IU of vitamin D" ratio is a formulation convention, not a validated number — no dose-ranging trial has tested a specific D-to-K2 ratio. Take K2 with a fatty meal. If you take warfarin or another vitamin K antagonist, do not start K2 without your physician.
Is vitamin K2 safe with blood thinners?
Not without medical oversight if the blood thinner is a vitamin K antagonist such as warfarin. Vitamin K opposes warfarin, and MK-7 at supplement doses (50 mcg or more) can interfere with it — consistency of intake matters. Newer direct oral anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban) do not work through vitamin K, so this interaction is not expected, but tell your physician either way.
Does vitamin K2 have side effects?
Vitamin K2 is very well tolerated — it has no established upper limit and no adverse effects have been reported at normal supplement doses. The one thing that matters is not a side effect but an interaction: K2 opposes warfarin and other vitamin K antagonists, so anyone on those medications should not start K2 without their doctor and INR monitoring.
When is the best time to take vitamin K2?
Take it with a meal that contains some fat, since K2 is fat-soluble. Beyond that, timing barely matters: MK-7 has a roughly three-day half-life, so morning versus night makes little difference — taking it consistently at the same time each day is more useful than any specific hour.
On this page
What are the main benefits of vitamin K2?
Two things, both traced to the same mechanism. K2 activates osteocalcin, a protein that binds calcium into bone, and matrix Gla protein (MGP), which keeps calcium out of artery walls — researchers sometimes call this the "calcium paradox," directing calcium toward the skeleton and away from the vasculature. In trials, that translates to a modest slowing of bone loss (a 3-year trial of 180mcg/day MK-7 slowed loss at the spine and femoral neck) and a modest improvement in arterial stiffness, a vascular marker, over the same timeframe. Neither is a dramatic effect, and neither is proof that K2 prevents fractures or heart attacks outright — it's a real but incremental benefit on the biology it's supposed to influence.
Does vitamin K2 really help with bone density?
Modestly, and the evidence is mixed rather than uniform. A 3-year trial of MK-7 at 180mcg/day slowed bone loss at the spine and femoral neck in postmenopausal women, though not at the total hip. Separately, Japanese trials found fewer vertebral and hip fractures using MK-4 at a much higher 45mg/day dose — but that evidence base is largely Japanese, several of the trials were open-label, and it hasn't reliably replicated in Western randomized trials. Treat vitamin K2 as a modest supporting factor for bone health, not a replacement for calcium, vitamin D, weight-bearing exercise, or prescribed osteoporosis treatment.
Can vitamin K2 prevent or reverse artery calcification?
Not the way it's often marketed. The mechanistic case is real — matrix Gla protein needs K2 to inhibit calcium deposition in artery walls, and mice bred without functional MGP die within two months from arterial calcification. In humans, a 3-year trial found 180mcg/day of MK-7 modestly improved arterial stiffness, and the Rotterdam Study linked higher dietary K2 intake to lower coronary heart disease risk. But that's stiffness and epidemiology, not proof of reversal — no trial has shown vitamin K2 dissolves calcium already deposited in arteries.
Do I need to worry about vitamin K2 if I take blood thinners?
If the blood thinner is warfarin or another vitamin K antagonist, yes — this is the one caution on this page that overrides the rest. Vitamin K opposes warfarin directly, and supplement-level MK-7 doses (roughly 50mcg or more) can interfere with your anticoagulation and swing your INR. Do not start, stop, or change vitamin K2 without your prescribing doctor involved. Newer blood thinners that aren't vitamin K antagonists — apixaban, rivaroxaban, dabigatran, edoxaban — don't work through this pathway, so the interaction isn't expected, but tell your doctor regardless.
Does vitamin K2 actually work for bone density?
Modestly, and the trials don't fully agree. A 3-year trial found 180mcg/day of MK-7 slowed bone loss at the spine and femoral neck, though not the total hip. A separate 3-year trial added MK-7 to vitamin D and calcium and improved carboxylation markers without changing bone density at all. It's a real but modest effect, not a substitute for osteoporosis treatment.
Does vitamin K2 clean out or reverse arterial calcification?
No — that specific claim isn't supported. K2 modestly improved arterial stiffness and a vitamin-K biomarker in one trial. But every recent, adequately powered trial that measured actual calcification — in aortic valves, diabetic arteries, and dialysis patients — came back negative. K2 supports the system that keeps calcium out of arteries; it does not dissolve calcium already deposited.
How strong is the arterial-stiffness evidence, really?
It's a real, measured result — but a surrogate one. A 3-year trial found 180mcg/day MK-7 modestly improved arterial stiffness and halved a vitamin-K-status marker, mainly in women with stiffer arteries at baseline. A separate observational study linked higher dietary K2 to lower heart-disease risk. Neither is proof that K2 prevents actual heart attacks or strokes.
Is the warfarin interaction something to worry about only after taking K2 for a while?
No — treat it as immediate. Vitamin K opposes warfarin, and even a single typical MK-7 capsule of 50mcg or more can be clinically relevant. Starting, stopping, or changing your K2 intake can swing your INR right away. If you take warfarin, this needs your doctor's involvement from your very first dose, not after weeks of watching.
How long does vitamin K2 take to work?
There's no short-term data to point to. The two landmark MK-7 trials both ran 3 years, and that's the only timeline this evidence base gives you. Neither trial reports an earlier checkpoint, so we can't say whether the benefit showed up in month 3 or month 30. Give it years, not weeks, and don't expect a fast signal.
How long until vitamin K2 improves bone density?
The trial that showed a benefit ran 3 years. MK-7 at 180mcg/day slowed bone loss at the spine and femoral neck in postmenopausal women, though not at the total hip. A separate 3-year trial of MK-7 plus D3 and calcium improved carboxylation markers but didn't change bone density at all. Bone is a slow-moving target either way.
How long until vitamin K2 improves arterial stiffness?
Also 3 years. That's when MK-7 at 180mcg/day modestly improved arterial stiffness and halved a vitamin-K-status biomarker in one trial. That's a real, measured result — but it's a biomarker and stiffness change, not proof that K2 prevents heart attacks or strokes.
Does the warfarin interaction happen on a timeline too?
No — treat it as immediate, not something you wait for. If you take warfarin, even a single typical K2 capsule can be clinically relevant and swing your INR. This isn't a slow-building effect like bone or artery benefits; it's a same-day interaction that needs your doctor's involvement from day one.
Vitamin K2 Benefits: Bone, Artery & Calcium Evidence
Ready to buy? See our best vitamin K2 ranked by dose, form, and cost →
The mechanism: the "calcium paradox"
Vitamin K2's benefits all trace back to one job: it's the cofactor that carboxylates — chemically activates — two calcium-handling proteins. Osteocalcin, made by bone-building cells, needs carboxylation to bind calcium into the bone matrix. Matrix Gla protein (MGP), made in blood vessel walls, needs carboxylation to inhibit calcium from depositing where it doesn't belong. Without enough K2, both proteins stay in their inactive, uncarboxylated form — measured in research as undercarboxylated osteocalcin and dephospho-uncarboxylated MGP (dp-ucMGP).
This is where the "calcium paradox" framing comes from: the same mineral that's essential for a strong skeleton is damaging when it deposits in arteries, and K2 is the switch that helps route it to the right place. The proof-of-concept is stark in animal research — mice engineered to lack functional MGP die within two months from arterial calcification (Luo 1997, PMID: 9052783). That's a mouse knockout model, not a human dose-response result, but it's the mechanistic foundation everything below builds on.
Bone density: modest and real, with a Japan-vs-West gap
The cleaner modern evidence uses MK-7. A 3-year trial gave healthy postmenopausal women 180mcg/day and found it slowed bone loss at the spine and femoral neck — though not at the total hip (Knapen 2013, PMID: 23525894). That's a real but partial effect, not a reversal of bone loss.
The older, higher-dose evidence uses MK-4 at a pharmaceutical scale: a systematic review and meta-analysis of vitamin K trials for fracture prevention found that high-dose MK-4 — the 45mg/day menatetrenone drug approved in Japan, roughly 250 times a typical MK-7 supplement dose — was associated with fewer vertebral and hip fractures (Cockayne 2006, PMID: 16801507). Here's the honest caveat the marketing usually skips: that meta-analysis pooled predominantly Japanese, often open-label trials, and this fracture-reduction finding has not reliably replicated in Western randomized trials. A dose-for-dose 45mg/day MK-4 protocol is a conversation to have with a doctor, not something to assume works the same way in a different population on a different diet. It also is not the same substance, at the same dose, as the MK-7 most supplements actually sell — see our MK-7 vs MK-4 comparison for why the two forms aren't interchangeable mcg-for-mcg.
Cardiovascular: the artery side of the calcium paradox
The same 3-year MK-7 trial design that showed a bone benefit also measured arterial stiffness, and at 180mcg/day it modestly improved stiffness while roughly halving the dp-ucMGP biomarker, mainly in women whose arteries were stiffer at baseline (Knapen 2015, PMID: 25694037). Separately, the Dutch Rotterdam Study — a large observational cohort — found that people with higher dietary menaquinone (K2) intake had a lower risk of coronary heart disease (Geleijnse 2004, PMID: 15514282).
Stay precise about what that evidence does and doesn't show. Arterial stiffness and a lower disease-risk association are not the same as proof that K2 reduces or reverses actual arterial calcification, and they are not proof it prevents heart attacks or strokes. For the full outcome-by-outcome breakdown — including why adequately powered trials that measured calcification directly came back negative — see our dedicated does vitamin K2 actually work? page.
MK-4 vs MK-7: does the form change the benefit?
Yes, materially, because the two forms behave completely differently in the body. MK-7 has a long half-life (around three days) and accumulates in the blood at supplement-sized microgram doses, which is why the modern bone and arterial-stiffness trials cited above used 90–200mcg/day. MK-4 clears within hours and is barely detectable in the blood at supplement doses, which is why the Japanese fracture trials needed a pharmaceutical 45mg/day (15mg three times daily) to show an effect. A bottle labeled "vitamin K2" doesn't tell you which benefit profile you're getting — the form and dose do. This distinction is the entire subject of our MK-7 vs MK-4 guide, including the all-trans quality issue and a full dose comparison table.
The one caution that overrides every benefit above: warfarin. Vitamin K2 chemically opposes warfarin and other vitamin K antagonists. Supplement-level MK-7 doses of roughly 50mcg or more can interfere with anticoagulation, and even small, inconsistent changes in K2 intake have destabilized warfarin patients (Schurgers 2007, PMID: 17158229). If you take warfarin or acenocoumarol, do not start, stop, or change vitamin K2 without your prescribing doctor and INR monitoring. Newer direct oral anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban) don't work through vitamin K, so this specific interaction isn't expected — but tell your doctor either way.
Vitamin K2 benefits at a glance
| Benefit | Mechanism | Strongest evidence | Honest caveat |
|---|---|---|---|
| Bone density (spine, femoral neck) | Carboxylates osteocalcin, binding calcium into bone | 3-year RCT, MK-7 180mcg/day (Knapen 2013) | Modest, not uniform across all bone sites; not a substitute for osteoporosis treatment |
| Fracture reduction | Same osteocalcin mechanism, pharmaceutical MK-4 dose | Meta-analysis of Japanese trials, MK-4 45mg/day (Cockayne 2006) | Largely Japanese/open-label evidence; has not reliably replicated in Western trials |
| Arterial stiffness | Carboxylates matrix Gla protein, inhibiting arterial calcium deposition | 3-year RCT, MK-7 180mcg/day (Knapen 2015) | A stiffness and biomarker result, not proof of reduced heart attack or stroke risk |
| Lower coronary heart disease risk | Same MGP mechanism, population-level | Rotterdam Study, dietary K2 intake (Geleijnse 2004) | Observational association, not a randomized outcome trial |
| "Cleaning" or reversing arterial calcification | Marketing claim beyond the mechanism | None — recent adequately powered calcification trials are negative | Not supported; see our does-it-work breakdown |
Does Vitamin K2 Actually Work? What the Evidence Shows
Ready to buy? See the best vitamin K2 picks, ranked by form quality and cost per day →
The verdict, by outcome
Vitamin K2 doesn't deserve one blanket yes-or-no. Bone and arterial stiffness have real but modest support; actual arterial calcification does not, and the warfarin risk sits apart from all of it:
| Outcome | Evidence | The honest read |
|---|---|---|
| Bone density (spine, femoral neck) | Modest but real | A 3-year trial of MK-7 180mcg/day slowed bone loss at the spine and femoral neck, not the hip. A separate 3-year trial found no bone-density change. |
| Arterial stiffness (surrogate marker) | Modest, surrogate-only | MK-7 180mcg/day improved stiffness and halved a vitamin-K biomarker over 3 years. Real, but a marker and stiffness result, not a heart-attack outcome. |
| Arterial calcification (actual) | Not supported | Every recent, adequately powered trial that measured real calcification — aortic valves, diabetic arteries, dialysis patients — came back negative. |
| MK-4 fracture protection (pharmaceutical dose) | Different question | Older Japanese trials found fewer fractures at 45mg/day MK-4, about 250x an MK-7 dose. Several were open-label — not comparable to a normal supplement. |
| Warfarin interaction (safety) | Real, established | Vitamin K opposes warfarin. Even one typical MK-7 capsule can be clinically relevant and swing your INR. |
If you're going to try it, this is what to buy
Any pick here applies to the bone and arterial-stiffness rows above, not to "cleaning out" arteries or the pharmaceutical MK-4 fracture protocol. NOW Foods MK-7 100mcg $0.22/day uses branded MenaQ7 — the all-trans, soy-free ingredient used in the trials cited above — at a dose inside their 90-200mcg range. For the same dose at lower cost, Nutricost MK-7 100mcg $0.07/day is a reasonable value alternative. Take it with a fatty meal, and if you're on warfarin, involve your doctor before starting either one. See every verified pick in the full vitamin K2 buying guide.
Bone density: modest but real, and the trials don't fully agree
A 3-year trial of MK-7 at 180mcg/day slowed bone loss at the spine and femoral neck — though not at the total hip — in postmenopausal women (Knapen 2013, PMID: 23525894). That's a real, if partial, benefit.
A separate 3-year trial added MK-7 to vitamin D and calcium and found improved carboxylation markers, but no change in bone density at all (Rønn 2021, PMID: 33030563). Two well-run 3-year trials, two different bone outcomes. The honest summary: K2's bone evidence is modest and real, not a guaranteed or uniform benefit.
Arterial stiffness vs actual calcification: the distinction that matters
The same 3-year MK-7 trial design that showed a bone benefit also tested arterial stiffness. At 180mcg/day, it modestly improved stiffness and halved a vitamin-K-status marker (dp-ucMGP), mainly in women whose arteries were stiffer at baseline (Knapen 2015, PMID: 25694037). An observational study separately linked higher dietary K2 intake to lower coronary heart disease risk (Geleijnse 2004, PMID: 15514282).
Here's where the marketing runs well ahead of the data. Stiffness and biomarkers are not the same as calcification. Every recent, adequately powered trial that measured actual calcification came back negative: an aortic-valve trial (Diederichsen 2022, PMID: 35465686), a diabetic-artery trial (Zwakenberg 2019, PMID: 31387121), and a dialysis-patient trial (Naiyarakseree 2023, PMID: 37299386). K2 supports the system that routes calcium away from arteries. It does not dissolve calcium that's already there.
MK-4 and fractures: a different question, a different dose
A pooled analysis of older Japanese trials found high-dose MK-4 — 45mg/day, about 250 times a typical MK-7 dose — associated with fewer vertebral and hip fractures (Cockayne 2006, PMID: 16801507). That's a genuine signal, but several of those trials were open-label and used a pharmaceutical-scale dose. It doesn't establish that the MK-7 most people actually buy prevents fractures at a normal supplement dose.
The warfarin caution: the one risk that isn't slow-building
Everything above is a years-long story. The warfarin interaction is not. Vitamin K opposes warfarin, and MK-7 at supplement doses of 50mcg or more can interfere with it (Schurgers 2007, PMID: 17158229). Even small, inconsistent changes in vitamin K intake have destabilized warfarin patients (Couris 2006, PMID: 16941417). If you take warfarin, this is a today conversation with your prescriber, not a wait-and-see one.
What vitamin K2 does not do
- It does not clean out or reverse arterial calcification. The adequately powered calcification trials were negative across the board.
- It does not reliably change bone density on its own. One 3-year trial found a spine and femoral-neck benefit; another found none.
- It is not proven to prevent heart attacks or strokes. The arterial evidence is a stiffness and biomarker result, not a hard outcome.
- It is not safe to combine with warfarin unsupervised. Even one capsule can matter — this needs your doctor from day one.
How Long Does Vitamin K2 Take to Work?
Know your dose already? See the best vitamin K2 picks, ranked by form quality and cost per day →
Timeline by Outcome
The table below lists only outcomes with a stated trial duration. Vitamin K2's bone and artery evidence comes from a small number of long-running trials, and none of them report an earlier interim result — they measured the endpoint at the end of the trial, not partway through.
| Outcome | What the Evidence Shows | Source-Trial Duration |
|---|---|---|
| Bone density (spine, femoral neck) | MK-7 180mcg/day slowed bone loss at the spine and femoral neck, but not the total hip, in postmenopausal women | Measured at 3 years (Knapen 2013) |
| Bone microarchitecture & density (with D3 + calcium) | MK-7 added to D3 and calcium improved vitamin-K carboxylation markers, but did not change bone density | Measured at 3 years (Rønn 2021) |
| Arterial stiffness | MK-7 180mcg/day modestly improved arterial stiffness (most clearly in women with stiffer arteries at baseline) and halved the dp-ucMGP biomarker | Measured at 3 years (Knapen 2015) |
Sources: Knapen MHJ, et al. Osteoporos Int. 2013. PMID 23525894; Knapen MHJ, et al. Thromb Haemost. 2015. PMID 25694037; Rønn SH, et al. Osteoporos Int. 2021. PMID 33030563 — all cited on our MK-7 vs MK-4 and dosage guide pages.
Why There's No Earlier Checkpoint
Both landmark MK-7 trials were designed as 3-year studies, and both report a single before-and-after comparison. Neither published an interim reading at 6 months or 1 year. That means we can honestly say the benefit was present by year 3 — we cannot say how early within that window it started.
Treat 3 years as the trial length these results are anchored to, not as "how long K2 takes to kick in." Nobody has tested whether a shorter course of MK-7 does anything measurable for bone or arteries.
What About MK-4 and Fractures?
Older Japanese trials of high-dose MK-4 (45mg/day) found fewer fractures in a pooled analysis. That's a genuine signal, but it doesn't belong in the table above: those trials used a different, pharmaceutical-scale form and dose, several were open-label, and a consistent trial duration isn't reported across them the way it is for the MK-7 studies. See our MK-7 vs MK-4 comparison for the full picture.
The Warfarin Interaction Isn't a "How Long" Question
Everything above is a slow-building effect measured after years of consistent use. The warfarin interaction works differently. Vitamin K opposes warfarin, and even a single typical MK-7 capsule (50mcg or more) can be clinically relevant. Starting, stopping, or changing your K2 intake can swing your INR right away.
If you take warfarin or another vitamin K antagonist, this isn't something to monitor after a few weeks — it needs your doctor and INR monitoring from your very first dose.
What to Take While the Evidence Builds
Trial-grade NOW Foods MK-7 Vitamin K2 100 mcg $0.22/day
All-trans MenaQ7 at 100mcg — the branded ingredient used in the trials above, at a dose inside their 90–200mcg range. Taking it doesn't shorten the years-long timeline; it just makes sure you're taking the form and dose the trials actually tested.
Check price →When to Reassess
For bone and arterial-stiffness benefits, think in years, not weeks or months. There is no published shorter-term checkpoint to judge against. If you're taking K2 for those reasons, consistency over years is the honest expectation the trials support — not a specific week to check back in.
For the warfarin interaction, there's no waiting period at all. Any change in your K2 intake is a today conversation with your prescriber, not a wait-and-see one.
More vitamin k2 guides
MK-7 vs MK-4 (Forms & Dosage)
Why the form decides the dose, how much to take with vitamin D, the all-trans quality issue, the warfarin caution, and an honest look at whether K2 does anything for arteries.
Best Vitamin K2 Supplement
Verified MK-7 picks ranked by form quality, all-trans content, and cost per day — plus the best D3+K2 combo and what to avoid.
About our data
Every guide draws on clinical evidence from PubMed systematic reviews and randomized trials (each citation verified against the primary source), with product picks ranked by form quality and cost per day. See our methodology and editorial standards.
Sources
- Knapen MHJ, et al. "Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women." Osteoporos Int. 2013;24(9):2499-507. PMID: 23525894
- Knapen MHJ, et al. "Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women." Thromb Haemost. 2015;113(5):1135-44. PMID: 25694037
- Cockayne S, et al. "Vitamin K and the prevention of fractures: systematic review and meta-analysis." Arch Intern Med. 2006;166(12):1256-61. PMID: 16801507
- Geleijnse JM, et al. "Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study." J Nutr. 2004;134(11):3100-5. PMID: 15514282
- Schurgers LJ, et al. "Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7." Blood. 2007;109(8):3279-83. PMID: 17158229
- Luo G, et al. "Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein." Nature. 1997;386(6620):78-81. PMID: 9052783
- Rønn SH, et al. "MK-7 on bone mineral density and microarchitecture (3-yr RCT)." Osteoporos Int. 2021. PMID: 33030563
- Diederichsen ACP, et al. "Vitamin K2 and D in Patients With Aortic Valve Calcification (AVADEC): a randomized trial." Circulation. 2022;145(18):1387-1397. PMID: 35465686
- Zwakenberg SR, et al. "The effect of menaquinone-7 supplementation on vascular calcification in patients with diabetes." Am J Clin Nutr. 2019;110(4):883-890. PMID: 31387121
- Naiyarakseree N, et al. "Effect of Menaquinone-7 Supplementation on Arterial Stiffness in Chronic Hemodialysis Patients." Nutrients. 2023;15(11):2570. PMID: 37299386
- Couris R, et al. "Dietary vitamin K variability affects INR." Int J Vitam Nutr Res. 2006. PMID: 16941417